Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Vericel Corporation (VCEL)

Vericel Corporation (VCEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Vericel Corporation 64 SIDNEY STREET CAMBRIDGE MA 02139 USA

www.vcel.com Employees: 398 P: 617-588-5555 F: 617-588-5554

Sector:

Medical

Description:

Vericel Corporation is focused on developing patient-specific expanded cellular therapies for use in the treatment of patients with severe diseases and conditions. The company markets two autologous cell therapy products in the United States: Carticel (R) for the treatment of cartilage defects in the knee, and Epicel (R) for the treatment of severe burns. It is also developing MACI (TM) for the treatment of cartilage defects in the knee, and ixmyelocel-T for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. Vericel Corporation, formerly Aastrom Biosciences, Inc., is based in United States.

Key Statistics

Overview:

Market Capitalization, $K 1,738,818
Enterprise Value, $K 1,638,728
Shares Outstanding, K 50,932
Float, K 48,284
% Float 94.80%
Short Interest, K 5,039
Short Float 9.89%
Days to Cover 9.54
Short Volume Ratio 0.55
% of Insider Shareholders 5.20%

Financials:

Annual Sales, $ 276,260 K
Annual Net Income, $ 16,520 K
Last Quarter Sales, $ 92,920 K
Last Quarter Net Income, $ 23,240 K
EBIT, $ 11,050 K
EBITDA, $ 22,630 K

Growth:

1-Year Return -17.80%
3-Year Return 13.50%
5-Year Return -40.90%
5-Year Revenue Growth 122.47%
5-Year Earnings Growth 433.33%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings 0.45 on 02/26/26
Next Earnings Date 05/14/26
Earnings Per Share ttm 0.31
EPS Growth vs. Prev Qtr 350.00%
EPS Growth vs. Prev Year 18.42%
Annual Dividend & Yield (Paid) 0.00 (0.00%)
Annual Dividend & Yield (Fwd) 0.00 (0.00%)
Dividend Payout Ratio 0.00%
Most Recent Split 1-20 on 10/16/13

VCEL Ratios

Ratio
Price/Earnings ttm 105.03
Price/Earnings forward 73.00
Price/Earnings to Growth N/A
Return-on-Equity % 5.17%
Return-on-Assets % 3.67%
Profit Margin % 5.98%
Debt/Equity 0.00
Price/Sales 6.00
Price/Cash Flow 58.61
Price/Book 4.64
Book Value/Share 7.01
Interest Coverage 28.59
60-Month Beta 1.20
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.